Sleepiness

Sleepiness (also known as drowsiness) is medically recognized as a state of near-sleep, or a strong desire for sleep without feeling a decrease in one's physical energy levels.^[1]^[2]^[3] This state is independent of a circadian rhythm^[1]; so, unlike sedation, this effect does not necessarily decrease physical energy levels but instead decreases wakefulness. It results in a propensity for tired, clouded, and sleep-prone behaviour. This can lead into a decreased motivation to perform tasks, as the increase in one's desire to sleep begins to outweigh other considerations. Prolonged exposure to this effect without appropriate rest can lead to cognitive fatigue and a range of other cognitive suppressions.

Sleepiness is most commonly induced under the influence of moderate dosages of a wide variety of compounds such as cannabinoids^[4], GABAergic depressants^[5]^[6], opioids^[7], antipsychotics^[8]^[9], some antihistamines^[10], and certain psychedelics such as LSA or 2C-C. However, it is worth noting that the few compounds which selectively induce this effect without a number of other accompanying effects are referred to as "hypnotics".

This effect seems to be mentioned within the following trip reports:

I slept for 27 hours

on 07/11/2020 - Julie

DPH 500mg oral
DXM 240mg oral

Experimenting with E-Cinnamal in combination with THC

on 6/3/2021 - Josie

E-Cinnamal 30mg Oral
THC 30mg Oral

Sleepy & Hungry Dreams

on 2022/05/04 - Marrub

Mirtazapine 75mg oral tablets, 15mg each

External Links

Somnolence (Wikipedia)

References

[1][2] American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.), 829. Arlington, VA: American Psychiatric Publishing. | https://doi.org/10.1176/appi.books.9780890425596.GlossaryofTechnicalTerms
Guilleminault, C., & Brooks, S. N. (2001). Excessive daytime sleepiness: a challenge for the practising neurologist. Brain, 124(8), 1482-1491. | https://doi.org/10.1093/brain/124.8.1482
Bereshpolova, Y., Stoelzel, C. R., Zhuang, J., Amitai, Y., Alonso, J. M., & Swadlow, H. A. (2011). Getting drowsy? Alert/nonalert transitions and visual thalamocortical network dynamics. Journal of Neuroscience, 31(48), 17480-17487. | https://doi.org/10.1523/JNEUROSCI.2262-11.2011
Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., ... & Collet, J. P. (2010). Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal, 182(14), E694-E701. | https://doi.org/10.1503%2Fcmaj.091414
Landauer, A. A., & Howat, P. (1983). Low and moderate alcohol doses, psychomotor performance and perceived drowsiness. Ergonomics, 26(7), 647-657. | https://doi.org/10.1080%2F00140138308963386
Greenblatt, D. J., Shader, R. I., & Abernethy, D. R. (1983). Current status of benzodiazepines. New England Journal of Medicine, 309(7), 410-416. | https://doi.org/10.1056%2FNEJM198308183090705
Corey, P. J., Heck, A. M., & Weathermon, R. A. (1999). Amphetamines to counteract opioid-induced sedation. Annals of Pharmacotherapy, 33(12), 1362-1366. | https://doi.org/10.1345/aph.19024
Van Putten, T., May, P. R., Marder, S. R., & Wittmann, L. A. (1981). Subjective response to antipsychotic drugs. Archives of General Psychiatry, 38(2), 187-190. | https://doi.org/10.1001%2Farchpsyc.1981.01780270073010
Artaloytia, J. F., Arango, C., Lahti, A., Sanz, J., Pascual, A., Cubero, P., ... & Palomo, T. (2006). Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. American Journal of Psychiatry, 163(3), 488-493. | https://doi.org/10.1176%2Fappi.ajp.163.3.488
Weiler, J. M., Bloomfield, J. R., Woodworth, G. G., Grant, A. R., Layton, T. A., Brown, T. L., ... & Watson, G. S. (2000). Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa driving simulator. Annals of Internal Medicine, 132(5), 354-363. | https://doi.org/10.7326%2F0003-4819-132-5-200003070-00004